Q-omics provides the consensus-scored MIR9-1HG profile across patient tissues and cancer cell-line models. MIR9-1HG expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR9-1HG is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, MIR9-1HG RNA expression shows 13,527 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUAD as cancer lineages where MIR9-1HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR9-1HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR9-1HG survival associations across molecular data types. MIR9-1HG RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR9-1HG RNA expression–survival associations across cancer types. High MIR9-1HG expression shows unfavorable associations in ACC, KIRP, ESCA, KICH and KIRC, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR9-1HG RNA expression.
This table summarizes MIR9-1HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MIR9-1HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR9-1HG shows lower tumor expression in BRCA and higher tumor expression in LUAD, KIRC, LIHC, LUSC and CHOL. The LUAD box plot shows higher MIR9-1HG RNA expression in tumor versus normal tissue (log2 FC = +0.675, t-test p < 0.001).
This table shows molecular features associated with MIR9-1HG in patient tissues and cancer cell lines. In patient samples, MIR9-1HG shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MIR9-1HG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
